In the document’s section dedicated to explaining adjustments for 2021, it begins with mentioning the changes to cannabis and psilocybin.
The DEA does not go into detail regarding why it is suddenly so interested in studying psilocybin and psilocyn in large quantities, but the substance has received a good amount of attention over the past year.
Many new studies are exploring the medical properties of the substance, and finding that it’s helpful in treating conditions like depression.
While the case in the United States Court of Appeals for the Ninth Circuit was dismissed on August 30, 2021, Circuit Judge Paul Watford wrote a statement as a part of his ruling that cannabis reclassification could be a possibility in the future.